The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.
AJTES Vol 6, No 1, January 2022
Hasani et al


mineralocorticoids antagonist
diabetic nephropathy
heart failure

How to Cite

Hasani, E., Rroji, M., & Barbullushi, M. (2022). The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients. Albanian Journal of Trauma and Emergency Surgery, 6(1), 1003-1006.


Inappropriate activation of the mineralocorticoid receptor (MR) plays a significant role in developing hypertension, the development of cardiac pathological changes, and chronic kidney disease (CKD), where death related to cardiovascular (CV) causes is the primary competing for the outcome to the progress to end-stage renal disease (ESRD) in patients with CKD.

Congestive heart failure (CHF) is a frequent comorbidity in patients with CKD. MR overactivation within the heart might cause coronary endothelial dysfunction, myocardial apoptosis, and reactive myocardial fibrosis and thus contribute to cardiac remodeling and its adverse consequences.

MR antagonists (MRAs) are evidence-based therapy in symptomatic patients with heart failure and reduced ejection fraction (HFrEF).

Finerenone, a novel, nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) with anti-inflammatory and antifibrotic effects, is a promising tool in treating heart failure in patients with T2DM and CKD.

It is felt to have higher potency and less hyperkalemia than steroidal MRAs such as spironolactone and eplerenone. It is unclear and a matter of discussion if it could be first-line therapy in this group of patients.

Conclusion: Nonsteroidal MRAs are currently tested in clinical trials. Based on preclinical and first clinical data, these nonsteroidal MRAs might overcome the limitations of today's steroidal antagonists.
Hasani et al


Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17. DOI: 10.1056/NEJM199909023411001. PMID: 10471456.

Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309–1321

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11–21.

Ruilope, L. M., Agarwal, R., Anker, S. D., Bakris, G. L., Filippatos, G., Nowack, C., Kolkhof, P., Joseph, A., Mentenich, N., Pitt, B., & FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. American journal of nephrology 2019; 50(5), 345–356.

Bauersachs J, Jasser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65(2):257-63.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC Scientific Document Group 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200).

MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35(1):30-4.

Wrenger E, Müller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327:147–9.

Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther 2005; 30:233–9.

Vlassopoulos D, Sonikian M, Dardioti V, et al. Insulin and mineralocorticoids influence extrarenal potassium metabolism in chronic hemodialysis patients. Ren Fail 2001; 23:833–42.

2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States (United States Renal Data System website). 2018.

Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015; 36:1437–1444. DOI: 10.1093/eurheartj/ehv010.

Edwards NC, Steeds RP, Chue CD, et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012; 73:447–54.

Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-161.

Bramlage P, Swift SL, Thoenes M, et al. Nonsteroidal mineralocorticoid receptor antagonism for treating cardiovascular and renal disease. Eur J Heart Fail 2016; 18:28–37.

Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y. Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol. 2008;294(6): F1287-95. doi: 10.1152/ajprenal.00017.2008. PMID: 18367662.

Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep. 2010;12(2):135-42. doi: 10.1007/s11906-010-0100-z. PMID: 20424957.

Belden Z, Deiuliis JA, Dobre M, Rajagopalan S. The role of the mineralocorticoid receptor in inflammation: Focus on kidney and vasculature. American Journal of Nephrology. 2017;46(4):298-314.

van der Heijden CDCC, Deinum J, Joosten LAB, Netea MG, Riksen NP. The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis. Cardiovasc Res. 2018;114(7):944-953. doi: 10.1093/cvr/cvy092. PMID: 29668907.

Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013; 9:459–469.

Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, Eitner F, Albrecht-Küpper B, Schäfer S. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist, protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014; 64:69–78.

Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, Brix S, Betz IR, Schupp M, Foryst-Ludwig A, Klopfleisch R, Stawowy P, Houtman R, Kolkhof P, Kintscher U. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity. Hypertension 2018; 71:599–608.

Gueret A, Haruki N, Favre J, Galmiche G, Nicol L, Henry JP, Besnier M, Thuillez C, Richard V, Kolkhof P, Mulder P, Jasser F, Ouvrard-Pascaud A. Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction. Hypertension. 2016;67(4):717-23.

Mulder P, BarreraChimal J, El Moghrabi S, Kolkhof P, Ouvrard-Pascaud A, Jaisser F Finerenone improves diastolic function in a preclinical model of type2 diabetes mellitus. Eur Heart J 2016; 37(Abstract Supplement):829

Kolkhof, Peter. [Handbook of Experimental Pharmacology] || Steroidal and Novel Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.2016; (Chapter 76), doi:10.1007/164_2016_76.

Rico-Mesa, Juan Simon; White, Averi; Ahmadian-Tehrani, Ashkan; Anderson, Allen S. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone. Current Cardiology Reports 2020; 22(11), 140–148. doi:10.1007/s11886-020-01399-7.

Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105-14.

Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. Circulation. 2021. doi: 10.1161/CIRCULATIONAHA.121.057983. Epub ahead of print. PMID: 34775784.

Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021;143(6):540-552.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.